Posted by admin on Jun 10th, 2022

Clever Leaves (NASDAQ:CLVR – Get Rating) and GSK (NYSE:GSK – Get Rating) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Clever Leaves has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

This table compares Clever Leaves and GSK’s net margins, return on equity and return on assets.

This table compares Clever Leaves and GSK’s revenue, earnings per share (EPS) and valuation.

GSK has higher revenue and earnings than Clever Leaves. Clever Leaves is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

31.7% of Clever Leaves shares are held by institutional investors. Comparatively, 32.8% of GSK shares are held by institutional investors. 8.8% of Clever Leaves shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

This is a summary of recent ratings for Clever Leaves and GSK, as provided by MarketBeat.com.

Clever Leaves presently has a consensus price target of $5.00, indicating a potential upside of 350.45%. Given Clever Leaves’ stronger consensus rating and higher probable upside, research analysts clearly believe Clever Leaves is more favorable than GSK.

GSK beats Clever Leaves on 9 of the 13 factors compared between the two stocks.

Clever Leaves Company Profile (Get Rating)

Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.

GSK Company Profile (Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive News & Ratings for Clever Leaves Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clever Leaves and related companies with MarketBeat.com's FREE daily email newsletter.

Liberty Energy Inc. (NYSE:LBRT) Major Shareholder Sells $204,552,500.00 in Stock

American Assets Trust, Inc. (NYSE:AAT) Expected to Announce Earnings of $0.54 Per Share